tiprankstipranks
Trending News
More News >

SSY Group’s Lornoxicam Gains Approval in China

Story Highlights
SSY Group’s Lornoxicam Gains Approval in China

Confident Investing Starts Here:

The latest announcement is out from SSY Group ( (HK:2005) ).

SSY Group Limited has announced that its product, Lornoxicam, has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the pharmaceutical industry by expanding its portfolio of pain management solutions.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company specializes in creating medications for pain management and other therapeutic areas, with a market focus on China.

YTD Price Performance: -10.70%

Technical Sentiment Signal: Buy

Current Market Cap: $1.13B

For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App